Photo from Aaron Goodman/X
Dec 12, 2023, 20:11
Aaron Goodman: ASH23 – I won’t be in attendance but my question would have been
Aaron Goodman shared a post on X/Twitter:
“ASH Plenary:
4 active drugs in myeloma makes more patients MRD negative then 3. Groundbreaking.
I won’t be in attendance but my question would have been “why not add teclistamab after IsaKRd” to make even more patients MRD negative.”
Source: Aaron Goodman/Twitter
Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 12, 2024, 21:03
Dec 12, 2024, 20:59
Dec 12, 2024, 20:55
Dec 12, 2024, 20:52
Dec 12, 2024, 20:49
Dec 12, 2024, 20:45
Dec 12, 2024, 20:39